Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes

Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes

Type 2 diabetes (T2D) is a multifaceted metabolic disorder associated with distinctive pathophysiological disturbances. One of the pathophysiological risk factors observed in T2D is dysregulation of the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1...

Full description

Bibliographic Details
Main Authors:	Jared Rosenberg, Jordan Jacob, Priya Desai, Jeremy Park, Lorin Donovan, Joon Young Kim
Format:	Article
Language:	English
Published:	Korean Society for the Study of Obesity 2021-09-01
Series:	Journal of Obesity & Metabolic Syndrome
Subjects:	glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide type 2 diabetes incretin oral glucose tolerance test insulin glucose
Online Access:	http://journaleditor.inforang.com/journal/view.html?doi=10.7570/jomes21053

Similar Items

Tirzepatide – a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023-10-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Effects of passage through the digestive tract on incretin secretion: Before and after birth
by: Seiichi Tomotaki, et al.
Published: (2021-06-01)

Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function: Review on Mathematical Modelling Approaches
by: Giovanni Pacini, et al.
Published: (2022-05-01)

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus
by: Sung Hoon Yu, et al.
Published: (2011-02-01)

Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
by: Chang Ho Ahn, et al.
Published: (2023-02-01)

The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
by: Soyeon Yoo, et al.
Published: (2021-06-01)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
by: Rizvi AA, et al.
Published: (2022-04-01)

Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury
by: Miaad Bader, et al.
Published: (2020-01-01)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation
by: Wathik Alsalim, et al.
Published: (2023-03-01)

Roles of glucose‐dependent insulinotropic polypeptide in diet‐induced obesity
by: Yusuke Seino, et al.
Published: (2022-07-01)

Glycemic and Metabolic Effects of Two Long Bouts of Moderate-Intensity Exercise in Men with Normal Glucose Tolerance or Type 2 Diabetes
by: Saeed Reza Eshghi, et al.
Published: (2017-07-01)

Variation in responses to incretin therapy: Modifiable and non-modifiable factors
by: Gregory O. Austin, et al.
Published: (2023-04-01)

Insulin and incretin responses to grazing in insulin‐dysregulated and healthy ponies
by: Danielle M. Fitzgerald, et al.
Published: (2019-01-01)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
by: Alexandros Leonidas Liarakos, et al.
Published: (2023-07-01)

Updates of incretin‐related drugs for the treatment of type 2 diabetes
by: Hirotaka Araki, et al.
Published: (2023-02-01)

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
by: Jonathan E. Campbell
Published: (2021-04-01)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
by: Martin Haljeta Friedrichsen, et al.
Published: (2023-12-01)

Insulin sensitivity, islet cell function, and incretin axis in pregnant women with and without gestational diabetes mellitus
by: Niya Narayanan, et al.
Published: (2024-01-01)

Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
by: Ondrej Krystynik, et al.
Published: (2023-01-01)

The Role of the Sweet Taste Receptor in Enteroendocrine Cells and Pancreatic β-Cells
by: Itaru Kojima, et al.
Published: (2011-10-01)

Abnormal gut microbiota and impaired incretin effect as a cause of type 2 diabetes mellitus
by: T. Y. Demidova, et al.
Published: (2022-03-01)

Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
by: Gemma Pujadas, et al.
Published: (2022-11-01)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
by: Enrique Z. Fisman, et al.
Published: (2021-11-01)

Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
by: Alessia Costa, et al.
Published: (2022-01-01)

Ingestion of coffee polyphenols increases postprandial release of the active glucagon-like peptide-1 (GLP-1(7–36)) amide in C57BL/6J mice
by: Yoshie Fujii, et al.
Published: (2015-01-01)

Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis
by: Akira Mima, et al.
Published: (2023-03-01)

Glucose‐dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in mice
by: Bo Ahrén
Published: (2022-10-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01)

Glucose-Dependent Insulinotropic Polypeptide Plasma Level Influences the Effect of n-3 PUFA Supplementation
by: Joanna Goralska, et al.
Published: (2022-08-01)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
by: Tsuyoshi Yanagimachi, et al.
Published: (2020-04-01)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
by: Juris J. Meier
Published: (2019-12-01)

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses
by: Line Engelbrechtsen, et al.
Published: (2018-03-01)

Acute Dose–Response Effectiveness of Combined Catechins and Chlorogenic Acids on Postprandial Glycemic Responses in Healthy Men: Results from Two Randomized Studies
by: Aya Yanagimoto, et al.
Published: (2023-02-01)

Nonglycemic effects of incretins in patients with long-term type 1 diabetes mellitus and chronic kidney disease
by: M S Arutyunova, et al.
Published: (2015-10-01)

Is the Secret in the Gut? SuperJump Activity Improves Bone Remodeling and Glucose Homeostasis by GLP-1 and GIP Peptides in Eumenorrheic Women
by: Sonya Vasto, et al.
Published: (2022-02-01)

Potential for Gut Peptide-Based Therapy in Postprandial Hypotension
by: Malcolm J. Borg, et al.
Published: (2021-08-01)

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
by: Bartłomiej Stachyra, et al.
Published: (2023-04-01)